Editor’s Note: Today is the day.

Our Lead Technical Tactician Nate Bear is doing a live demo of his AI-powered scanner – S.A.M. at 2 p.m. EST.

This is your chance to see how Nate finds A+ trade setups in seconds.

He’ll also be looking for actionable trades using this scanner.

Click here to sign up for this free event today before it’s too late.

– Ryan Fitzwater, Publisher

Anyone who’s followed U.S. Secretary of Health Robert Kennedy Jr. knows he’s expressed public skepticism about vaccine safety and efficacy.

And yesterday – several pharma companies saw a dip after RFK Jr. announced he was firing the entire CDC Vaccine Advisory Committee.

Moderna led all companies with a 1% drop, and Novavax (NVAX) was also down 1%.

It’s not the first time vaccine companies have fallen on RFK Jr. news.

Back in January, the sector fell after RFK Jr. was officially nominated for U.S. Secretary of Health.

However, I believe this latest RFK news is an overreaction and could provide more buy opportunities on several pharma companies.

Here are a few worth keeping an eye on.

No. 1 – Merck (MRK)

My colleague Bryan named Merck one of his top value plays for 2025 back in January.

In fact, during the height of the Trump tariff wars in March, Merck was one of the few pharmaceutical companies still thriving.

It provides strong fundamentals, and one of the highest dividends on the dow.

But even more important – Merck has several top-selling vaccines, including Gardasil/Grdasil 9, which is used to prevent HPV-related cancers and diseases.

No. 2 – Sanofi Company

Sanofi is a Paris-based global healthcare company with top-selling vaccine Beyfortus, a respiratory syncytial virus antibody for infants.

Beyfortus generated $1.8 billion globally in 2024, achieving “blockbuster” status in its first year.

Sanofi expects that number to double by the end of 2025, and recently ramped up its Beyfortus production for the third quarter to ensure availability as immunizations begin in early fall.

No. 3 – GSK plc

GSK (GlaxoSmithKline) is a British biotech company, with a top selling vaccine to help with Shingles called Shingrix.

It generated about $900 million in Q1, getting the company off to a strong start in 2025 with growth in sales, profits and earnings.

Action Plan: Overall, my bullish case for these companies is simple – there’s strong demand for vaccines. Plus, there’s even more potential for more drug breakthroughs as technology like artificial intelligence evolves.

So this short-term volatility news of RFK Jr.’s firing of the vaccine committee is nothing to panic over.

I’m tracking all 3 of these companies in The War Room for potential trades, and we’re currently positioned on Pfizer (PFE).

Click here to join The War Room and see where the millionaires trade.